Bone Sarcomas

(P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA

(P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS

(P 53) CURATIVE-INTENT SURGERY FOR A SOLITARY ISOLATED BONE METASTASIS FROM EXTREMITY SARCOMA: WHO UNDERWENT METASTASECTOMY AND WHAT WAS THE PROGNOSTIC OUTCOME?

(P 54) HIGH-THROUGHPUT DRUG SCREENING IN CHONDROSARCOMA CELLS IDENTIFIES MULTIPLE EFFICIENT ANTINEOPLASTIC AGENTS

(P 55) RELATIVE WASH-IN RATE ON DYNAMIC CONTRAST-ENHANCED MRI AS A NEW PROGNOSTIC FACTOR IN PATIENTS WITH OSTEOSARCOMA; A POSSIBLE TOOL FOR PERSONALIZED SARCOMA-CARE?

(P 56) CHARACTERIZATION OF DENOSUMAB TREATMENT RESPONSE ON MR PERFUSION IN GIANT CELL TUMORS OF BONE

(P 57) REAL-WORLD EXPERIENCE OF CABOZANTINIB IN PAEDIATRIC, TEENAGE AND YOUNG ADULT (TYA) AND ADULT METASTATIC BONE SARCOMA PATIENTS FROM THE LONDON SARCOMA SERVICE (LSS)

(P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING

(P 59) CHONDROSARCOMA OF THE FLAT BONES: DIFFERENTIAL SURVIVAL BETWEEN HIGH GRADE LESIONS OF THE PELVIS AND SCAPULA

(P 60) SKIP LESIONS IN CHONDROSARCOMA: IS WHOLE BONE IMAGING NECESSARY?

(P 61) ADJACENT VENOUS TUMOR THROMBUS IN PRIMARY OSTEOSARCOMA OF THE PELVIS AND EXTREMITIES

(P 62) PROSTHESIS-ASSOCIATED SARCOMA: A REVIEW OF 8 HIGH-GRADE LESIONS ARISING AROUND A TOTAL JOINT ARTHROPLASTY IMPLANT

(P 63) EVALUATION OF LOCAL RECURRENCE AND DIAGNOSTIC DISCORDANCE IN CHONDROSARCOMA PATIENTS UNDERGOING PREOPERATIVE BIOPSY

(P 64) OSTEOSARCOMA. PATIENT-DERIVED XENOGRAFTS MODELS TO RECAPITULATE PATIENTS' CHEMORESISTANCE AND METASTATIC DISEASE

(P 65) PROFILING EXTRACELLULAR VESICLES AND NANOPARTICLES IN OSTEOSARCOMA

(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA

(P 67) GENOMIC CHARACTERIZATION OF CHONDROSARCOMA: A RARE SARCOMA WITH CLINICAL RESPONSES TO IMMUNE CHECKPOINT INHIBITION

(P 68) METASTASIS-DIRECTED RADIOTHERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

(P 69) DEVELOPMENT AND MISSION OF THE HARMONIZATION INTERNATIONAL BONE SARCOMA CONSORTIUM (HIBISCUS)

(P 70) ICONIC (IMPROVING OUTCOMES THROUGH COLLABORATION IN OSTEOSARCOMA): A PROSPECTIVE OBSERVATIONAL COHORT STUDY FOR NEWLY DIAGNOSED OSTEOSARCOMA PATIENTS IN THE UNITED KINGDOM (UK)

(P 71) CHEMOTHERAPY AND PROGNOSTIC SIGNIFICANCE OF EXTENT OF DEDIFFERENTIATION IN DEDIFFERENTIATED PAROSTEAL OSTEOSARCOMA

(P 72) CO-EXPRESSION OF LEUKOCYTE CYTOSOLIC PROTEIN 1 AND MATRIX METALLOPROTEINASES ARE INTEGRAL FOR METASTATIC PROGRESSION OF CHONDROSARCOMA

(P 73) FOSTER CONSORTIUM, FIGHT OSTEOSARCOMA THROUGH EUROPEAN RESEARCH

(P 74) SACRAL CHORDOMA: A RANDOMIZED & OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO). INTERIM ANALYSIS

(P 75) REAL-WORLD DATA ON REGORAFENIB AND CABOZANTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OSTEOSARCOMA AND EWING SARCOMA INCLUDED IN THE SACHA-FRANCE STUDY

(P 76) GENETIC EVIDENCE OF METACHRONOUS DEDIFFERENTIATION OF CHONDROSARCOMA AT A DISTANT SITE

(P 77) PATIENT OUTCOMES AFTER OPEN VERSUS CORE NEEDLE BIOPSY IN LOWER EXTREMITY SARCOMA

(P 78) THE CLINICAL OUTCOME OF EXTRASKELETAL MYXOID CHONDROSARCOMA

(P 79) HEAD AND NECK OSTEOSARCOMA: THE EXPERIENCE OF 52 CASES FROM A SINGLE TERTIARY INSTITUTION OVER 25 YEARS

(P 80) OPTIMIZING DOSE OF MAP THERAPY FOR CHILDREN, YOUNG ADULTS AND ADULTS WITH OSTEOSARCOMA; A SINGLE-CENTRE RETROSPECTIVE ANALYSIS

(P 81) OPTIMIZING EWING SARCOMA AND OSTEOSARCOMA BIOPSY ACQUISITION: CONSENSUS RECOMMENDATIONS FROM THE CHILDREN'S ONCOLOGY GROUP BONE TUMOR COMMITTEE

(P 82) PROGNOSTIC FACTORS AND OUTCOMES OF 275 PATIENTS WITH HEAD AND NECK BONE AND SOFT TISSUE SARCOMA: A SINGLE CENTRE COHORT STUDY

(P 84) CSF1R OVEREXPRESSION ACCELLERATES OSTEOSARCOMA TUMOR FORMATION AND GENERATES TUMORS WITH DECREASED IMMUNE CELL INFILTRATION

(P 85) TARGETING CD99 ELICITS EWING SARCOMA CELL PHAGOCYTOSIS BY UNDIFFERENTIATED AND M2-LIKE MACROPHAGES AND INDUCES MACROPHAGE POLARIZATION TOWARD A M1-LIKE PHENOTYPE

(P 86) DECIPHERING CELL-MATRIX INTERACTIONS IN OSTEOSARCOMA RESPONSE TO CHEMOTHERAPY IN A 3D TISSUE-ENGINEERED IN VITRO MODEL

(P 87) ANGIOSARCOMA OF THE ILIUM TREATED WITH HEMIPELVECTOMY AND HIP TRANSPOSITION FOLLOWED BY POSTOPERATIVE CHEMOTHERAPY WITH PAZOPANIB: A CASE REPORT

(P 89) GENERATION OF CHONDROCYTE-DERIVED MOUSE OSTEOSARCOMA MODELS - TRACKABLE SYSTEMS TO DELINEATE ONCOGENIC AND METASTATIC ENVENTS PRIOR TO TUMOROGENESIS

(P 90) RESULTS FROM AN INTERNATIONAL SURVEY OF BONE SARCOMA PATIENTS

(P 91) BLOOD TRANSFUSION AND SURVIVAL AMONG CHILD, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY

(P 92) DOSIMETRIC CHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH EXTRACRANIAL CHORDOMAS AND CHONDROSARCOMAS TREATED WITH HIGH DOSE RADIOTHERAPY: A LARGE SINGLE INSTITUTION COHORT

(P 93) INDETERMINATE CHEST LESIONS IN PATIENTS WITH BONE SARCOMA INCIDENTAL FINDING VERSUS METASTATIC DISEASE

(P 94) DEVELOPING NOVEL OLIGONUCLEOTIDE THERAPIES TO MODULATE INSULIN RECEPTOR ALTERNATIVE SPLICING IN PEDIATRIC BONE SARCOMAS

(P 95) LONG-TERM OUTCOMES OF PATIENTS DIAGNOSED WITH CHORDOMA OF THE SACRUM

(P 96) LEPTOMENINGEAL RECURRENCE OF EWING'S SARCOMA: A CASE SERIES